Press Release

View printer-friendly version
<< Back
Aeglea BioTherapeutics to Present at Evercore ISI HealthconX Conference
Company to Webcast Fireside Chat on Tuesday, November 27 at 2:45 p.m. ET

AUSTIN, Texas, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, will participate in a fireside chat at the Evercore ISI HealthconX Conference in Boston, MA on Tuesday, November 27.

Presentation Details
Date: Tuesday, November 27, 2018
Time: 2:45 p.m. ET
Location: The Boston Harbor Hotel, Boston, MA
Room: South Atlantic Room (2nd floor)
Webcast: http://ir.aegleabio.com/events/event-details/evercore-isi-healthcare-conference-2018

To access the live and archived audio webcast of the fireside chat, visit the Presentations & Events section of the Aeglea BioTherapeutics investor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. Replays of the webcast will be available for 30 days thereafter.

About Aeglea BioTherapeutics
Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. Aeglea is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas. For more information, please visit http://aegleabio.com.

Investor Contact:
Joey Perrone
Director, Finance & Investor Relations
Aeglea BioTherapeutics
investors@aegleabio.com

Media Contact:

David Calusdian
Sharon Merrill Associates
617.542.5300
AGLE@investorrelations.com

LOGO-AEGLEA-RGB_small.jpg

Source: Aeglea BioTherapeutics, Inc.